Interviews

Stephen Bell

SVP Analytical Solutions & Customer Enablement

2024-12-20

In the next year, we will accelerate our innovation pipeline by bringing to market a series of new products, consolidate our operational footprint as a standalone business, achieve solid sales growth, and enhance our distribution platforms. By leveraging our innovative products and addressing emerging trends such as AI, these efforts will enable us to serve customers faster and more effectively while capitalizing on trends in pharma and applied markets like semiconductor, battery, and environmental testing to generate growth in our key markets.

Laura Niklason

President & CEO

Humacyte

2024-12-20

Humacyte is a biotechnology company specializing in the development of bioengineered human tissues, notably universally implantable, lab-grown blood vessels, aimed at transforming vascular medicine and improving patient outcomes.

Andrew Power

President & CEO

Digital Realty

2024-12-19

Growth requires significant investment, whether in expansive data halls or land and connectivity infrastructure. As a 20-year public company, we’ve mastered leveraging public and private capital to future-proof our customers’ growth. This ability to blend technical and financial strengths enables us to serve our customers while maintaining a robust trajectory for the business.

David Walls

President & CEO

Austin Industries

2024-12-18

We have diversified our operations beyond oil and petrochemical industries into sectors like food processing, which helps us weather market fluctuations. Given the current focus on fixing supply chain issues and rebuilding American manufacturing, we believe this wave of development will continue for much longer than most people anticipate.

Mark Herbert

VP of Biopharma Business Development

Varda Space Industries

2024-12-17

Varda Space Industries specializes in processing pharmaceuticals in microgravity and safely returning them to Earth for further development and commercialization.

Christina Crawford Kosmowski

CEO

LogicMonitor

2024-12-16

By 2030, the U.S. will be reshaped by a new era of hyper-connected, AI-driven digital ecosystems - fully automated and fueled by real-time data. LogicMonitor will be central to this shift, serving as the intelligence layer that enables businesses to thrive in this high-stakes environment.

Juan Font

CEO

CoreSite

2024-12-16

Data centers are a cornerstone of digital infrastructure, and their role will only expand with AI’s growth. The U.S., as a leader in AI technology, must prioritize maintaining this position. For our part, we are ensuring sufficient capacity in land and power to continue serving customers, while broader solutions to these energy challenges will require multi-party commitment.

Paula Brown Stafford

CEO

Allucent

2024-12-13

Allucent is a global contract research organization (CRO) that provides comprehensive drug development solutions, including regulatory strategy, clinical operations, and biometrics, with a focus on supporting small and mid-sized biotech companies in bringing new therapies to market.

Jeanne Hecht

CEO & Chairwoman

Lexitas

2024-12-10

Lexitas is a specialized contract research organization (CRO) focused exclusively on ophthalmology, providing clinical trial management, regulatory support, and advanced imaging solutions for eye-related diseases and treatments.

Don Graves

19th Deputy Secretary of Commerce

U.S. Department of Commerce

2024-12-10

The U.S. has been a leader in technology development, but we lost ground in semiconductor manufacturing by not maintaining production capabilities. Now, with the Chips Act, we are working to regain that ground and prevent dependency on adversaries for critical technologies.

Pagina 14 din 154